News | May 03, 2011

Being Tall, Obese May Increase Risk of Deep Vein Blood Clots

May 3, 2011 – Being tall and obese may increase your risk for potentially dangerous blood clots, according to new research in Arteriosclerosis, Thrombosis and Vascular Biology: Journal of the American Heart Association.

Obesity is a well-known risk factor for clots in deep veins (usually in the legs) and for pulmonary embolism, a clot in blood vessels of the lungs that can result in sudden death or strain on the heart. Together, the two conditions are called venous thromboembolism (VTE).

Compared with short (5 feet, 7.7 inches or less) and normal-weight men (body mass index < 25kg/m2), the age-adjusted risk of VTE was:

• 5.28 times higher in obese and tall men

• 2.57 times higher in normal-weight and tall men (at least 5 feet, 11.7 inches tall)

• 2.11 times higher in obese and short men

 

Compared with short (5 feet, 2.6 inches or less) normal-weight women, the age-adjusted risk of VTE was:

• 2.77 times higher in obese and tall women

• 1.83 times higher in obese and short women

• Not increased in normal-weight and tall women (more than 5 feet, 6 inches)

The amount of risk conferred by being both obese and tall was comparable to other known risk factors for VTE, including pregnancy, the use of oral contraceptives and carrying one gene for an inherited predisposition to clotting called Factor V Leiden.

"We believe that we observed the increased risk in tall and normal-weight men, but not women, because most women do not get sufficiently tall," said Sigrid K. Braekkan, Ph.D., senior study author and a researcher in the Hematological Research Group at the University of Tromso in Norway. "The risk may be present in very tall women, but there were too few to investigate this properly."

Researchers said more studies are needed to determine the mechanisms of the association between tall stature, excess weight and the combination on the risk of VTEs.

"In tall people the blood must be pumped a longer distance by the calf-muscle pump, which may cause reduced flow in the legs and thereby raise the risk of clotting," Braekkan said. "Understanding and preventing VTE is important because even the first occurrence may be fatal. Obesity, in combination with other VTE risk factors, has been shown to substantially increase the risk, so we wanted to assess the combined effects of tall stature and obesity."

The research team analyzed data from the Tromso study, which conducts periodic health surveys of adults 25-97 years old in the Norwegian town. Researchers collected height and obesity measures on 26,714 men and women followed a median of 12.5 years between 1994 and 2007. During that time, 461 VTEs occurred.

Obesity causes increased pressure in the abdomen, which may reduce the ability of the calf-muscle pump to return the blood from the legs. "Obesity is also linked to a state of constant low-grade inflammation, and inflammation may render blood more susceptible to clotting," Braekkan said.

Physicians should consider people's height and weight as they assess their overall risk for dangerous clots, researchers said.

"Since body height is not easy to modify, the most important thing is to stay slim, especially if you are tall," Braekkan said.

The researchers previously found a strikingly similar rise in clot risk along with height in American men, and believe that the height cut-offs would apply to Caucasian populations in other regions.

In the United States, more than 275,000 people each year are hospitalized with deep vein clots or pulmonary embolism, according to the American Heart Association.

The University of Tromso and the Northern Norway Regional Health Authority funded the study.

For more information: www.americanheart.org


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now